The Oncotype IQ Genomic Intelligence Platform

The Journey to Serve 1 Million Cancer Patients with Oncotype DX Tests

Making Cancer Care Smarter

As the world's leading provider of genomic-based diagnostic tests, we're committed to making cancer care smarter with our Oncotype IQ Genomic Intelligence Platform. This expanding suite of tissue- and liquid-based tests answers specific questions across the patient journey—from diagnosis through treatment and ongoing cancer management-through a single, trusted source easily accessed via our secure web-based platform for physicians to interpret and share results with patients.

Oncology and Urology Channels

Oncotype DX

Our flagship line of gene expression tests has been used to guide treatment decisions for more than 1 million breast, colon, and prostate cancer patients worldwide.

Oncotype IQ Platform Evolution

Oncotype DX AR-V7 Nucleus Detect

Launched recently in collaboration agreement with Epic Sciences, this liquid biopsy-based assay helps men with metastatic prostate cancer determine the most effective, life-sustaining therapy. Performed in Epic Science's CLIA-certified laboratory, the test will detect the expression of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells. Learn more

The Road Ahead

Looking ahead, we will continue to expand our Oncotype IQ platform through internal development programs and strategic partnerships, all with the goal of making cancer care smarter.

Delivering Healthcare Savings


More than $100 Billion is spent each year on cancer care. Precision medicine can make a difference.

The Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx) definitively showed how Oncotype DX distinguishes the vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy from those for whom chemotherapy can be life-saving.

Learn More

Our Newest Test

For patients with metastatic castration resistant prostate cancer

Learn More

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™